ATYR1923 Found Safe, Effective for Pulmonary Sarcoidosis Patients

ATYR1923 Found Safe, Effective for Pulmonary Sarcoidosis Patients

306472

ATYR1923 Found Safe, Effective for Pulmonary Sarcoidosis Patients

aTyr Pharma’s experimental therapy ATYR1923 safely and effectively improves lung function and reduces symptoms in adults with pulmonary sarcoidosis, while lowering the need for oral corticosteroids, top-line data from a Phase 1b/2a clinical trial show. Notably, while all three tested therapy doses were well-tolerated, greater clinically meaningful improvements were observed with the higher dose, 5 mg/kg, according to researchers. “We are delighted by the results of this study, which provide the first clinical proof-of-concept for…

You must be logged in to read/download the full post.